Table 3.

Results from testing compounds in a genetic model of generalised seizures: the DBA/2 mouse model of audiogenic seizures

Drug	Latency (s) to convulsions (mean±s.e.m)	P
Vehicle (i.p.)	10.9 ± 2.6	–
Orphenadrine (12.5 mg/kg i.p.)	40.0 ± 5.6	6.10 × 10–5
Orphenadrine (25 mg/kg i.p.)	53.4 ± 3.7	5.40 × 10–7
Orphenadrine (50 mg/kg i.p.)	60.0 ± 0.0	4.14 × 10–7
Dyclonine (5 mg/kg i.p.)	31.5 ± 6.2	1.77 × 10–2
Dyclonine (10 mg/kg i.p.)	44.7 ± 5.4	2.16 × 10–4
Dyclonine (20 mg/kg i.p.)	57.7 ± 2.4	4.14 × 10–7
Trimeprazine (2.5 mg/kg i.p.)	11.0 ± 20.6	6.52 × 10–1
Trimeprazine (5 mg/kg i.p.)	18.1 ± 4.1	1.77 × 10–2
Trimeprazine (10 mg/kg i.p.)	44.5 ± 5.3	4.06 × 10–6
Acamprosate (125 mg/kg i.p.)	8.7 ± 0.4	6.40 × 10–1
Acamprosate (250 mg/kg i.p.)	9.2 ± 0.2	4.56 × 10–1
Acamprosate (500 mg/kg i.p.)	14.3 ± 2.5	1.20 × 10–2
Betahistine (75 mg/kg i.p.)	9.1 ± 0.5	4.53 × 10–1
Betahistine (150 mg/kg i.p.)	6.9 ± 0.4	2.83 × 10–2
Betahistine (300 mg/kg i.p.)	5.3 ± 0.3	4.48 × 10–5
Valproate (180 mg/kg i.p.)	57.7 ± 1.4	4.89 × 10–7

After activation of a bell, latency to the occurrence of tonic convulsions and clonic convulsions was measured. P, Benjamini–Hochberg-corrected P-value from two-sided Mann–Whitney U test; s.e.m, standard error of the mean.